Saturday, June 25, 2016 5:19:00 PM
It is extremely unlikely that Seymour, Diwan or his wife would be making the kind of money they are making from NNVC. Remember, the 30% mark up on all direct and indirect expenses, plus salary, bonus and friends and family shares. Their families have already cashed out millions.
What would Seymour or Diwan be making in the real world? Would seymour go back to private practice (very unlikely as that has never been his thing) and Diwan wouldn't be making high 6- low 67 figures a year as a lab tech for a big pharma.
The shorts are and day traders are enjoying the slow but steady return they have been able to active for the past 6-7 years due to tyne company's inability to make any real progress.
The reason NNVC goes to outside labs is to make the announcement that they are "working" with these credible institutions and scientists/professors. They are trying to position it as an endorsement of the platform. "We're working with these fine reputable institutions, we must therefore be fine and reputable." But as I've been saying, these are labs for hire and will take on just about ANY outside work. It's surprising that nobody questions why NNVC can say they have no control over when these outside partners will actually get to testing their product, when they are paying them. Just another way to passed the buck for why NOTHING ever gets done. Nothing.
Let's talk about the product. They can't make it. That's what matters. They haven't had any of their test results independently verified. That's what matters. They can not seem to stay focused on any single treatment, regardless of how many times they say it is their singular "laser like" focus.
Flucide, MERS, Dengue, HIV, Ebola…all at a stand still because they are NOW focusing on Herpecide…until they announce Zika.
Wait for it.
Recent NNVC News
- NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • InvestorsHub NewsWire • 05/02/2024 02:07:42 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:53:32 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 02/14/2024 09:55:35 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/19/2024 09:44:48 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 12/04/2023 09:08:49 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 10/13/2023 08:30:41 PM
- Form NT 10-K - Notification of inability to timely file Form 10-K 405, 10-K, 10-KSB 405, 10-KSB, 10-KT, or 10-KT405 • Edgar (US Regulatory) • 09/28/2023 08:44:54 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 09/01/2023 08:46:45 PM
- Clinical Trial of Broad-Spectrum Antiviral Drug NV-CoV-2 is Progressing Well, Says NanoViricides - NV-CoV-2 is Positioned to Fulfill Many Unmet Medical Needs • InvestorsHub NewsWire • 07/06/2023 03:16:37 PM
NanoViricides Reports that the Phase I NV-387 Clinical Trial is Completed Successfully and Data Lock is Expected Soon • NNVC • May 2, 2024 10:07 AM
ILUS Files Form 10-K and Provides Shareholder Update • ILUS • May 2, 2024 8:52 AM
Avant Technologies Names New CEO Following Acquisition of Healthcare Technology and Data Integration Firm • AVAI • May 2, 2024 8:00 AM
Bantec Engaged in a Letter of Intent to Acquire a Small New Jersey Based Manufacturing Company • BANT • May 1, 2024 10:00 AM
Cannabix Technologies to Deliver Breath Logix Alcohol Screening Device to Australia • BLO • Apr 30, 2024 8:53 AM
Hydromer, Inc. Reports Preliminary Unaudited Financial Results for First Quarter 2024 • HYDI • Apr 29, 2024 9:10 AM